Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trifluoromethanesulfonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL8407011 | 0.89 | CA1 (0.44) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL117027 | 0.89 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL28079246 | 0.86 | CA1 (0.41) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL4318160 | 0.86 | CA1 (0.41) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL796767 | 0.86 | CA1 (0.41) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL5623900 | 0.85 | GPR3 (0.34) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL11765237 | 0.83 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL1293248 | 0.83 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL25301943 | 0.82 | CA1 (0.44) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL25292878 | 0.82 | CA1 (0.44) | GPR3CA1CA2CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421100-B1 | CHEMICAL SYNTHESIS OF SOLAMARGINE | GLYCOMED SCIENCES LTD (KY) | 2008-07-09 | — | — | EP | disclosed |
| US-20040259814-A1 | Synthesis of solanum glycosides | GLYCOMED SCIENCES LIMITED (KY) | 2004-12-23 | — | — | US | disclosed |
| EP-1421100-A1 | CHEMICAL SYNTHESIS OF SOLAMARGINE | GlycoMed Sciences Limited (AU) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003018604-A1 | SYNTHESIS OF SOLANUM GLYCOSIDES | GLYCOMED SCIENCES LIMITED (AU) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259814-A1 | Synthesis of solanum glycosides | GALE, MGAM, STS | GPR3 2586/4885CA1 2575/4885CA2 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.